These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9302741)

  • 1. Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs.
    Gupta RK; Collier RJ; Rappuoli R; Siber GR
    Vaccine; 1997; 15(12-13):1341-3. PubMed ID: 9302741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
    Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.
    Bröker M
    Hum Vaccin Immunother; 2016 Mar; 12(3):664-7. PubMed ID: 26327602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid.
    Porro M; Saletti M; Nencioni L; Tagliaferri L; Marsili I
    J Infect Dis; 1980 Nov; 142(5):716-24. PubMed ID: 6780629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin.
    Rydell N; Sjöholm I
    Vaccine; 2005 Apr; 23(21):2775-83. PubMed ID: 15780725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.
    Stickings P; Peyre M; Coombes L; Muller S; Rappuoli R; Del Giudice G; Partidos CD; Sesardic D
    Infect Immun; 2008 Apr; 76(4):1766-73. PubMed ID: 18227167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.
    Anderson P; Pichichero ME; Insel RA
    J Clin Invest; 1985 Jul; 76(1):52-9. PubMed ID: 3874882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
    McNeela EA; Jabbal-Gill I; Illum L; Pizza M; Rappuoli R; Podda A; Lewis DJ; Mills KH
    Vaccine; 2004 Feb; 22(8):909-14. PubMed ID: 15161067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres.
    Gupta RK; Griffin P; Rivera R; Siber GR
    Dev Biol Stand; 1998; 92():277-87. PubMed ID: 9554282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
    Rydell N; Sjöholm I
    Vaccine; 2004 Mar; 22(9-10):1265-74. PubMed ID: 15003656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.
    Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR
    Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs.
    Johansen P; Moon L; Tamber H; Merkle HP; Gander B; Sesardic D
    Vaccine; 1999 Sep; 18(3-4):209-15. PubMed ID: 10506644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant.
    Mariotti S; Teloni R; von Hunolstein C; Romagnoli G; Orefici G; Nisini R
    Vaccine; 2002 May; 20(17-18):2229-39. PubMed ID: 12009277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
    Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR
    Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C.
    Mazzantini RP; Miyaji EN; Dias WO; Sakauchi D; Nascimento AL; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Vaccine; 2004 Jan; 22(5-6):740-6. PubMed ID: 14741167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the non-toxic mutant of the diphtheria toxin K51E/E148K as carrier protein for meningococcal vaccines.
    Pecetta S; Vijayakrishnan B; Romano MR; Proietti D; Lo Surdo P; Balocchi C; Mori E; Davis BG; Berti F
    Vaccine; 2016 Mar; 34(11):1405-11. PubMed ID: 26845738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toxin-neutralizing properties of antibodies to diphtheria toxin recombinant subunits A and B and a new method of their estimation].
    Kaberniuk AA; Oliĭnyk OS; Kolybo DV; Komisarenko SV
    Ukr Biokhim Zh (1999); 2009; 81(3):92-101. PubMed ID: 19877434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study.
    Togashi T; Mitsuya N; Kogawara O; Sumino S; Takanami Y; Sugizaki K
    Vaccine; 2016 Aug; 34(38):4635-4641. PubMed ID: 27265451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody induction method in mice for the potency assays of diphtheria and tetanus components in combined vaccines.
    Maheshwari SC; Sharma SB; Kumar A; Sokhey J
    J Commun Dis; 1998 Sep; 30(3):139-46. PubMed ID: 10093418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.